# Endometriosis

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred                     | Generic Name | Quantity | Time (Days) |
| :---------------------------- | :----------- | :------: | :---------: |
| Danazol <sup>ST</sup>                    |              |          |             |
| Depo-Subq Provera 104 <sup>ST</sup>      |              |          |             |
| Lupaneta Pack <sup>ST</sup>              |              |          |             |
| Lupron Depot <sup>QL ST</sup> 3.75, 11.25 MG |              |          |             |
| Myfembree <sup>QL ST</sup>                 |             |         |           |
| Orilissa <sup>ST</sup>                   |              |          |             |
| Zoladex <sup>ST</sup>                    |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Synarel       |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Step Therapy Criteria

- Must have had an inadequate clinical response of at least **84 days** with at least **one preferred** NSAID and **one preferred** oral contraceptive 

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **84 days** with at least **one preferred** NSAID, **one preferred** oral contraceptive, AND **one preferred** step-therapy drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=55)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=21)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
